"Promotion results" in experiments on a vaccine to prevent Alzheimer's

Help a new vaccine aimed at a protein that causes Alzheimer’s disease to eliminate toxic cells in mice with this disease. Researchers at the University of “Jonando” in Japan have developed the vaccine to eliminate the Sheikh cells that express the protein associated with the aging of the brain. Two years ago, scientists at the same university tested another vaccine on mice and managed to improve many age -related diseases, including atherosclerosis and type 2 diabetes in mice. The new vaccine is aimed at Sheikh cells and is a phenomenon known in cell biology, which expresses a permanent stop of the cell cycle, and occurs in response to different pressure, including DNA damage or cellular functional imbalance. And when the cells age, they stop sharing and subject to different changes in genetic expression and cellular function. The Sheikh cells secrete a mixture of protein and inflammatory molecules, combined as the “apparently associated with aging” or SASP. This style contains factors that can improve inflammation and reform tissue, which can have effects on aging and age -related diseases. Several previous studies have indicated that the proteins and inflammatory molecules are secretly secreted in the glial cells in people with Alzheimer’s disease, and based on the results of these studies, the researchers tested this vaccine on mice to target the sheikh cells to treat the disease. After vaccination, mice had less than these molecules in the brain tissue and also showed an improvement in behavior and awareness. A potential prevention key, and the new vaccine, may be the key to preventing Alzheimer’s disease or adjusting its course according to a preliminary research presented in the scientific sessions of the American Heart Association conference. Alzheimer’s disease represents 50% to 70% of dementia patients around the world. If the success of the vaccine is proven in humans, it will be an excellent step to postpone the development of the disease or even prevent it. The research team has created a mouse model with Alzheimer’s disease, in a way that mimics the human brain caused by the toxic protein event, known as ‘beta amyloid’, and for the vaccine efficiency test, the mice were treated at two months and four months with the control vaccine or a soft -vaccine. Usually, at the late stage of Alzheimer’s disease, people do not have anxiety, which means they are not aware of the things around them, while the mice receiving the vaccine suffer from anxiety, which means they were more careful and more aware of the things around them, which indicates a decrease in the severity of the disease. The vaccine has significantly reduced the “beta amyloid” deposits in the brain tissue in the brain shortex, which is responsible for the treatment of language, attention and problem solving. It appears that the star cell, which is the most abundant type of glial cells in the brain and is a specific inflammatory molecule, decreases in size in the mice that receive the vaccine. A decrease in other important inflammatory indicators has also been observed, which means that inflammation in the brain can improve the vaccine response. The behavior test on mice at the age of 6 months revealed that the mice that received the vaccine responded better to their environment of the mice that received the vaccine of the placebo. The mice that received the new vaccine tend to act like regular healthy mice and showed more awareness of their environment. It appears that the vaccine has strengthened the proteins called near specialized brain cells, small glial cells, which play a role in the immune defense of the central nervous system. Small glial cells help to remove harmful plates that consist of protein, but this leads to encephalitis that can damage nerve cells and increase the person’s cognitive decline, which may be one of the reasons for the development of Alzheimer’s disease. The new vaccine can help solve a global crisis that is constantly increasing. With the age of the world, the number of individuals with Alzheimer’s disease is expected to increase significantly, leading to a great burden on public health. The new vaccine can contribute to reducing the cost of patient care, increasing the possibility of early intervention for individuals who are at risk of developing the disease, and to increase healthy aging by reducing the risk of cognitive decline and dementia in the elderly. Also read: